Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals
Actinogen Medical is developing a promising oral treatment for Alzheimer's and depression and is accelerating clinical trials with new capital.
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Latest Threads
Tag | Subject | ||||||
---|---|---|---|---|---|---|---|
A01 | Ann:EGM Result (Price Sensitive) | 11/11/21 | 0 | 411 | |||
|
|||||||
A01 | Ann:Notice to CDI Holders (Price Sensitive) | 12/10/21 | 0 | 346 | |||
|
|||||||
A01 | Ann:Notice of Extraordinary Meeting (Price Sensitive) | 10/10/21 | 0 | 454 | |||
|
|||||||
A01 | Ann:Preliminary Report for the end of 30 June 2021 (Price Sensitive) | 13/09/21 | 0 | 277 | |||
|
|||||||
A01 | Ann:Half Yearly Report for the end of 30 June 2021 (Price Sensitive) | 13/09/21 | 0 | 332 | |||
|
|||||||
A01 | Ann:Notice of intention to delist (Price Sensitive) | 26/08/21 | 0 | 367 | |||
|
|||||||
A01 | Ann:AGM Result 2021 (Price Sensitive) | 03/08/21 | 0 | 363 | |||
|
|||||||
A01 | Ann:Notice of Annual General Meeting (Price Sensitive) | 28/07/21 | 0 | 401 | |||
|
See All Discussions